Compare Amgen, Inc. (AMGN) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Roundhill Magnificent Seven ETF — how do they compare? Amgen, Inc. trades at $413.74 (market cap $224.14B), while Roundhill Magnificent Seven ETF trades at $67.98. The key difference: Amgen, Inc. pays a 2.43% dividend while Roundhill Magnificent Seven ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Roundhill Magnificent Seven ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | MAGS | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $417.20 | $70.94 |
52-Week Low | $271.18 | $55.39 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
MAGS trades at $67.95, down 1.58% today, with technical indicators showing a bullish moving average trend but overbought RSI levels. The ETF holds equal-weighted exposure to the Magnificent Seven tech stocks, which have underperformed the broader market this year amid shifting investor focus toward semiconductors and AI infrastructure. Recent news highlights concerns over aggressive AI capital spending pressuring dividends and buybacks.
The outlook remains cautious as AI profit realization lags expectations, though hyperscaler valuations are compressed. Key risks include concentration in tech, high expectations, and macroeconomic sensitivity. Analyst sentiment is mixed, with some seeing long-term AI potential but near-term headwinds from earnings pressure and market rotation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
